ZNF217 and breast cancer: In a case-control study involving 1,083 blood samples (healthy women versus breast cancer patients), lack of methylation of the same ZNF217 exon predicted increased breast cancer risk (26), allowing the authors to propose the DNA methylation status at this ZNF217 locus to be a surrogate biomarker of breast cancer risk.